Evidence map›Paper›PMID 35006245›Full record

Trial reportJAMA network open2022

Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.

Helen C Stankiewicz Karita, Tracy Q Dong, Christine Johnston, Kathleen M Neuzil, Michael K Paasche-Orlow, Patricia J Kissinger, Anna Bershteyn, Lorna E Thorpe, Meagan Deming, Angelica Kottkamp and 16 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 1 country.

Helen C Stankiewicz KaritaDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Tracy Q DongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Christine JohnstonDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Kathleen M NeuzilDepartment of Medicine, University of Maryland School of Medicine, Baltimore.
Michael K Paasche-OrlowDepartment of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Patricia J KissingerDepartment of Epidemiology, Tulane University, New Orleans, Louisiana.
Anna BershteynDepartment of Population Health, New York University Grossman School of Medicine, New York.
Lorna E ThorpeDepartment of Population Health, New York University Grossman School of Medicine, New York.
Meagan DemingDepartment of Medicine, University of Maryland School of Medicine, Baltimore.
Angelica KottkampDepartment of Medicine, New York University Grossman School of Medicine, New York.
Miriam LauferDepartment of Medicine, University of Maryland School of Medicine, Baltimore.
Raphael J LandovitzDepartment of Medicine, University of California, Los Angeles, Los Angeles.
Alfred LukDepartment of Medicine, Tulane University, New Orleans, Louisiana.
Risa HoffmanDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.
Pavitra RoychoudhuryVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Alexander L GreningerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Meei-Li HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mark WenerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle.
Connie CelumDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Helen Y ChuDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Jared M BaetenDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Anna WaldDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Ruanne V BarnabasDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Elizabeth R BrownVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
University of Washington · USFred Hutch Cancer Center · USUniversity of Maryland, Baltimore · USNew York University · USTulane University · USBoston Medical Center · USUniversity of California, Los Angeles · US

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA TrialR01CA213130 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MADELEINE, MARGARET M, WALD, ANNA · 2017 to 2022
$4.6M
NCI NIH HHS R01 CA213130NIAID NIH HHS UM1 AI148684
6 · The paper itself

Abstract

Importance: The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development. Objective: To characterize early SARS-CoV-2 viral RNA load (hereafter referred to as viral load) in individuals with incident infections in association with COVID-19 symptom onset and severity. Design, Setting, and Participants: This prospective cohort study was a secondary data analysis of a remotely conducted study that enrolled 829 asymptomatic community-based participants recently exposed (<96 hours) to persons with SARS-CoV-2 from 41 US states from March 31 to August 21, 2020. Two cohorts were studied: (1) participants who were SARS-CoV-2 negative at baseline and tested positive during study follow-up, and (2) participants who had 2 or more positive swabs during follow-up, regardless of the initial (baseline) swab result. Participants collected daily midturbinate swab samples for SARS-CoV-2 RNA detection and maintained symptom diaries for 14 days. Exposure: Laboratory-confirmed SARS-CoV-2 infection. Main Outcomes and Measures: The observed SARS-CoV-2 viral load among incident infections was summarized, and piecewise linear mixed-effects models were used to estimate the characteristics of viral trajectories in association with COVID-19 symptom onset and severity. Results: A total of 97 participants (55 women [57%]; median age, 37 years [IQR, 27-52 years]) developed incident infections during follow-up. Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle threshold [Ct] value, 38.5 [95% CI, 38.3-39.0]), 18 (19%) for 2 to 6 days (median Ct value, 36.7 [95% CI, 30.2-38.1]), and 31 (32%) for 7 days or more (median Ct value, 18.3 [95% CI, 17.4-22.0]). The cycle threshold value has an inverse association with viral load. Six participants (6%) had 1 to 6 days of viral shedding with censored duration. The peak mean (SD) viral load was observed on day 3 of shedding (Ct value, 33.8 [95% CI, 31.9-35.6]). Based on the statistical models fitted to 129 participants (60 men [47%]; median age, 38 years [IQR, 25-54 years]) with 2 or more SARS-CoV-2-positive swab samples, persons reporting moderate or severe symptoms tended to have a higher peak mean viral load than those who were asymptomatic (Ct value, 23.3 [95% CI, 22.6-24.0] vs 30.7 [95% CI, 29.8-31.4]). Mild symptoms generally started within 1 day of peak viral load, and moderate or severe symptoms 2 days after peak viral load. All 535 sequenced samples detected the G614 variant (Wuhan strain). Conclusions and Relevance: This cohort study suggests that having incident SARS-CoV-2 G614 infection was associated with a rapid viral load peak followed by slower decay. COVID-19 symptom onset generally coincided with peak viral load, which correlated positively with symptom severity. This longitudinal evaluation of the SARS-CoV-2 G614 with frequent molecular testing serves as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.

Indexed as

RNA, ViralSARS-CoV-2Severity of Illness IndexViral LoadVirus SheddingAdultCOVID-19FemaleHumansIncidenceLongitudinal StudiesMaleMiddle AgedMolecular Diagnostic TechniquesPolymerase Chain ReactionProspective StudiesRNA, Viral

Identifiers

PMID35006245
PMCPMC8749477
OpenAlexW4205707138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.